JNJ

229.26

+0.59%↑

ISRG

516

-2.16%↓

ABT

106.31

-1.83%↓

MDT

100.22

-0.73%↓

131.29

-2.73%↓

JNJ

229.26

+0.59%↑

ISRG

516

-2.16%↓

ABT

106.31

-1.83%↓

MDT

100.22

-0.73%↓

131.29

-2.73%↓

JNJ

229.26

+0.59%↑

ISRG

516

-2.16%↓

ABT

106.31

-1.83%↓

MDT

100.22

-0.73%↓

131.29

-2.73%↓

JNJ

229.26

+0.59%↑

ISRG

516

-2.16%↓

ABT

106.31

-1.83%↓

MDT

100.22

-0.73%↓

131.29

-2.73%↓

JNJ

229.26

+0.59%↑

ISRG

516

-2.16%↓

ABT

106.31

-1.83%↓

MDT

100.22

-0.73%↓

131.29

-2.73%↓

Strona główna・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

4.46 -3.04

Buy Sell

Overview

Share price change

24h

Current

Min

4.41

Max

4.58

Key metrics
By Trading Economics
Income	9.6M -162M
Sales	-14M 5.2M
Profit margin	-3,135.324
Employees	800
EBITDA	6.4M -141M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+68.48% upside

Dividends
By Dow Jones
Next Earnings	27 lut 2026

Market Stats
By TradingEconomics
Market Cap	18M 2.4B
Previous open	7.5
Previous close	4.46

News Sentiment

By Acuity

50%

133 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

4.15 / 4.75 Support & Resistance

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 sty 2026, 23:51 UTC

Earnings

Correction to Samsung Fourth-Quarter Net Profit Article

28 sty 2026, 23:49 UTC

Hot Stocks

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 sty 2026, 23:19 UTC

Earnings

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 sty 2026, 22:43 UTC

Earnings

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 sty 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 sty 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 sty 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 sty 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 sty 2026, 23:49 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 sty 2026, 23:30 UTC

Market Talk

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 sty 2026, 23:28 UTC

Earnings

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 sty 2026, 23:26 UTC

Earnings

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 sty 2026, 23:21 UTC

Earnings

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 sty 2026, 23:18 UTC

Earnings

Acquisitions, Mergers, Takeovers

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 sty 2026, 22:58 UTC

Earnings

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 sty 2026, 22:48 UTC

Market Talk

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 sty 2026, 22:45 UTC

Earnings

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 sty 2026, 22:44 UTC

Earnings

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 sty 2026, 22:43 UTC

Earnings

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 sty 2026, 22:41 UTC

Earnings

Hot Stocks

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 sty 2026, 22:41 UTC

Market Talk

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 sty 2026, 22:41 UTC

Earnings

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 sty 2026, 22:40 UTC

Earnings

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 sty 2026, 22:39 UTC

Earnings

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 sty 2026, 22:38 UTC

Earnings

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 sty 2026, 22:37 UTC

Earnings

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 sty 2026, 22:35 UTC

Earnings

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 sty 2026, 22:26 UTC

Market Talk

Earnings

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 sty 2026, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

28 sty 2026, 22:20 UTC

Market Talk

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

68.48% upside

12 Months Forecast

Average 7.75 USD 68.48%

High 11 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

133 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.